Amgen vaccine triggers immune response in advanced melanoma -study
March 14, 2014 at 17:15 PM EDT
March 14 (Reuters) - An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.